Goldman Sachs’s PTC Therapeutics PTCT Stock Holding History

Goldman Sachs’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-27,500	Closed	-$1.4M	–	5503
2020 Q2	$1.4M	Buy	+27,500	New	+$1.35M	﹤0.01%	3727
2018 Q2	–	Sell	-96,000	Closed	-$2.6M	–	5933
2018 Q1	$2.6M	Buy	+96,000	New	+$2.43M	﹤0.01%	3403
2017 Q1	–	Sell	-59,000	Closed	-$644K	–	6955
2016 Q4	$644K	Buy	+59,000	New	+$619K	﹤0.01%	4831
2016 Q1	–	Sell	-16,200	Closed	-$525K	–	7267
2015 Q4	$525K	Sell	16,200 -88,900	-85%	-$2.62M	﹤0.01%	4881
2015 Q3	$2.81M	Buy	105,100 +88,400	+529%	+$3.78M	﹤0.01%	3438
2015 Q2	$804K	Sell	16,700 -47,500	-74%	-$2.77M	﹤0.01%	4729
2015 Q1	$3.91M	Buy	+64,200	New	+$3.92M	﹤0.01%	3130

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs's PTCT Position: Q1 2026 in Review

Goldman Sachs reduced its PTC Therapeutics (PTCT) stake by 19% in Q1 2026, selling an estimated $13.8M and leaving 827,631 shares worth $56.4M. The position accounts for 0.01% of the portfolio, ranked #1484.

Goldman Sachs first reported a position in PTCT in Q3 2013 and has held it in 49 quarters since. The position peaked at $77.7M in Q4 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

Goldman Sachs held 827,631 shares of PTC Therapeutics worth $56.4M as of Q1 2026.
Goldman Sachs sold 195,460 PTC Therapeutics shares in Q1 2026, an estimated $13.8M.
PTC Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1484 holding.
Goldman Sachs first reported a position in PTC Therapeutics in Q3 2013 and has held it in 49 quarters since.
Goldman Sachs's PTC Therapeutics position peaked at $77.7M in Q4 2025.
349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.